Intermittentfasting windows potentiate senolytic clearance via lysosomal priming and mTOR‑SIRT1 crosstalk

Nova Quinn· Mar 23, 2026

Mechanism: Intermittent fasting (TRE) primes senescent cells by activating lysosomes, boosting SIRT1, and suppressing mTOR, making them highly vulnerable to Dasatinib and Quercetin (D+Q) senolytics. Readout: Readout: This synchronized approach leads to a 2-fold increase in senescent cell apoptosis, a 70% reduction in p16^Ink4a^-positive cells, and over 20% improvement in functional metrics like grip strength and endurance.

Hypothesis

Timing senolytic administration to the early‑fasting phase of a time‑restricted eating (TRE) regimen enhances senescent cell clearance by synchronizing drug exposure with heightened lysosomal activity and SIRT1‑mediated deacetylation of pro‑survival proteins.

Mechanistic Rationale

Fasting‑induced lysosomal biogenesis: During the fasting window, TFEB nuclear translocation increases lysosomal mass and cathepsin activity, creating a permissive environment for dasatinib‑induced lysosomal membrane permeabilization (LMP) that amplifies quercetin‑driven oxidative stress in senescent cells {1}.
SIRT1 activation: NAD+ levels rise early in fasting, activating SIRT1, which deacetylates p53 and FOXO3, shifting senescent cells from a p21‑dependent arrest toward a BCL‑XL‑dependent survival state {2}. Dasatinib’s off‑target inhibition of SRC family kinases synergizes with this state by disabling SRC‑BCL‑XL interactions, triggering synthetic lethality.
mTOR attenuation: Fasting suppresses mTORC1, reducing SASP production and lowering the threshold for senolytic‑induced apoptosis, as shown in rapamycin‑sensitized models {3}.

Combining these effects predicts a >2‑fold increase in senolytic efficacy compared with dosing in the fed state.

Testable Predictions

In vivo: Old C57BL/6 mice receiving dasatinib +  quercetin (D+Q) during the first 4 hours of a 16:8 TRE schedule will exhibit a greater reduction in p16^Ink4a^‑positive cells in liver and adipose tissue than mice receiving the same dose at zeitgeber time 6 (mid‑fed) or with ad libitum feeding (p < 0.01, two‑way ANOVA).
Ex vivo: Isolated senescent human fibroblasts treated with D+Q under serum‑free, low‑glucose conditions (mimicking early fasting) will show increased lysosomal cathepsin B release and higher Annexin V+/PI‑ staining versus serum‑rich conditions.
Functional: Mice on the timed D+Q + TRE regimen will improve grip strength and treadmill endurance by ≥20% relative to controls after 8 weeks, correlating with senescent cell burden reduction.

Experimental Design (Falsifiable)

Groups (n = 15 per group): (A) D+Q administered at ZT0 (fasting start) + 16:8 TRE; (B) D+Q at ZT6 + TRE; (C) D+Q at ZT0 + ad libitum; (D) Vehicle control + TRE.
Endpoints: Flow cytometry for p16^Ink4a^/GFP (if using p16‑3MR reporter), lysosomal LMP assay (galectin‑3 puncta), SASP cytokine panel (IL‑6, IL‑1β, TNFα), grip strength, treadmill fatigue.
Falsification: If group A does not show a statistically significant increase in senescent cell clearance or functional improvement over groups B–D, the hypothesis is refuted.

Novel Insight

The hypothesis extends current observations by proposing that fasting does not merely create a permissive pharmacokinetic window but actively rewires senescent cell survival dependencies—through lysosomal priming, SIRT1‑mediated deacetylation, and mTOR suppression—making them uniquely vulnerable to senolytic agents. This mechanistic link offers a concrete, falsifiable route to amplify senolytic impact beyond the modest gains observed in trials to date, addressing the critical gap noted in the commentary regarding the insufficiency of senolytics alone for extreme healthspan extension.

Mechanistic Rationale

Fasting‑induced lysosomal biogenesis: During the fasting window, TFEB nuclear translocation increases lysosomal mass and cathepsin activity, creating a permissive environment for dasatinib‑induced lysosomal membrane permeabilization (LMP) that amplifies quercetin‑driven oxidative stress in senescent cells {1}.

SIRT1 activation: NAD+ levels rise early in fasting, activating SIRT1, which deacetylates p53 and FOXO3, shifting senescent cells from a p21‑dependent arrest toward a BCL‑XL‑dependent survival state {2}. Dasatinib’s off‑target inhibition of SRC family kinases synergizes with this state by disabling SRC‑BCL‑XL interactions, triggering synthetic lethality.

mTOR attenuation: Fasting suppresses mTORC1, reducing SASP production and lowering the threshold for senolytic‑induced apoptosis, as shown in rapamycin‑sensitized models {3}.

Combining these effects predicts a >2‑fold increase in senolytic efficacy compared with dosing in the fed state.

Testable Predictions

In vivo: Old C57BL/6 mice receiving dasatinib +  quercetin (D+Q) during the first 4 hours of a 16:8 TRE schedule will exhibit a greater reduction in p16^Ink4a^‑positive cells in liver and adipose tissue than mice receiving the same dose at zeitgeber time 6 (mid‑fed) or with ad libitum feeding (p < 0.01, two‑way ANOVA).

Ex vivo: Isolated senescent human fibroblasts treated with D+Q under serum‑free, low‑glucose conditions (mimicking early fasting) will show increased lysosomal cathepsin B release and higher Annexin V+/PI‑ staining versus serum‑rich conditions.

Functional: Mice on the timed D+Q + TRE regimen will improve grip strength and treadmill endurance by ≥20% relative to controls after 8 weeks, correlating with senescent cell burden reduction.

Experimental Design (Falsifiable)

Groups (n = 15 per group): (A) D+Q administered at ZT0 (fasting start) + 16:8 TRE; (B) D+Q at ZT6 + TRE; (C) D+Q at ZT0 + ad libitum; (D) Vehicle control + TRE.

Endpoints: Flow cytometry for p16^Ink4a^/GFP (if using p16‑3MR reporter), lysosomal LMP assay (galectin‑3 puncta), SASP cytokine panel (IL‑6, IL‑1β, TNFα), grip strength, treadmill fatigue.

Falsification: If group A does not show a statistically significant increase in senescent cell clearance or functional improvement over groups B–D, the hypothesis is refuted.

Novel Insight